Claims, Evidence & Scientific Credibility / Service
Evidence strategies that integrate clinical data, real-world evidence, patient-reported outcomes, consumer behavior, adverse event data, concomitant-use evidence, and international precedent — built around the question the evidence has to answer.
The Work
The evidence base that decides a label, a claim, a switch case, or an investor decision is no longer clinical-only. Real-world evidence, patient-reported outcomes, consumer-behavior data, adverse event signal, concomitant-use evidence, and international precedent all carry weight — and FDA, FTC, payers, retailers, and diligence teams increasingly expect to see them integrated. The companies that stall are usually not short of data. They are short of a strategy that connects the data they have, the data they need, and the specific decision the evidence has to support.
RGM treats evidence as a strategy, not a pile. The work starts from the downstream decision — the label change, the claim, the Rx-to-OTC switch case, the FDA meeting, the investor diligence cycle, the portfolio positioning move — and works backward to define what evidence actually has to do. International precedent is part of that picture: EU and Japan regulatory decisions, in particular, often inform what is feasible and defensible in the U.S. context. RWE is structured around the decision it has to inform, not generated for its own sake. PROs and consumer-behavior evidence are designed to land with the audience that will ultimately review them. The output is an evidence plan a leadership team, a board, or an FDA review division can work with.
Companies preparing for an Rx-to-OTC switch, an FDA meeting where the evidence story matters, a label expansion, an investor diligence cycle, or a portfolio-level positioning decision. Brands trying to figure out what evidence to invest in next.
A written evidence strategy tied to specific business decisions; a prioritized evidence-investment plan; a comparative international precedent analysis; or a defensible argument that an existing evidence base supports a specific use.
More in This Pillar
